MedTrace Logo

ACute and Chronic Effects of Saxagliptin

NCT01521312 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-02-03

No results posted yet for this study

Summary

Glucose ACCES study will explore the acute and long term (12-week treatment) effects of saxagliptin in patients with impaired glucose tolerance during fasting and after a standardised breakfast. The investigations will be performed on:

* glycemic parameters
* on cardiovascular parameters

Conditions

  • Impaired Glucose Tolerance

Interventions

DRUG

saxagliptin

5mg a day for 11-14 weeks

OTHER

placebo pill

one tablet a day for 11-14 weeks

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Paul Valensi, MD · Jean Verdier Hospital - Department of Endocrinology-Diabetology-Nutrition

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01521312 on ClinicalTrials.gov